Study of Adjuvant Radiochemotherapy for Gastric Cancer

Stomach Neoplasms Clinical Trial

Official title:

Prospective Phase I/II Study of Adjuvant Radiochemotherapy for Gastric Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00188266
• Other study ID #: UHN REB 02-0134-C
• Status: Completed
• Phase: Phase 1/Phase 2
• First received: September 9, 2005
• Last updated: September 19, 2017
• Start date: August 2002
• Est. completion date: August 18, 2017

Study information

• Verified date: September 2017
• Source: University Health Network, Toronto
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In 1991, the South West Oncology Group (SWOG) conducted a randomized study of adjuvant chemotherapy (5-fluorouracil and folinic acid) with concurrent radiation (4500 cGy/25 fractions) versus surgery alone for patients with completely resected gastric carcinoma.

This landmark study showed the benefit of adjuvant treatment for gastric cancer and radically changed the treatment of this disease. However, the resulting standard treatment has severe acute toxicity, and despite this advance, 50% of patients still die of gastric cancer. The investigators hope to develop a modified protocol using active chemotherapy agents, but with reduced acute toxicity. Such an approach could ultimately be studied against the current SWOG approach to determine whether or not the addition of cisplatinum improves efficacy.

Patients who decide to participate in the study will receive a chemotherapy drug called 5-Fluorouracil (5FU)through an intravenous catheter continuously over 12 weeks. Patients will not be admitted to hospital to receive the chemotherapy but will need to wear a waist pack to carry a small pump that will deliver the medication. They will however need to make regular visits to have their medication bags changed. Patients will also receive Cisplatin intravenously every 2 weeks for 4 doses. In addition, patients will also receive radiation to their stomach, lymph nodes, and the area where they had their surgery. This study also comprise of a questionnaire for us to see how patient's cancer and treatment is affecting their quality of life. Patients will have regular follow-up by their physicians.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 65
• Est. completion date: August 18, 2017
• Est. primary completion date: December 19, 2013
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• R0 resection (no microscopic residual) of adenocarcinoma of stomach or gastroesophageal (GE) junction, prior to starting chemotherapy and radiation

• Tumor must not extend more than 2 cm along the esophagus; bulk of the tumor must be in the stomach.

• Adequate pre-operative cross-sectional imaging (computed tomography [CT] or magnetic resonance imaging [MRI])

• International Union Against Cancer (UICC)/American Joint Committee on Cancer (AJCC) Stage IB - IV, excluding patients with metastatic disease (T1N1, T2N0 to T4N1, N2, and any T, N3). T2N0 eligible only if disease extends beyond muscularis propria.

• No previous abdominal radiotherapy or contraindication to radiotherapy

• Eastern Cooperative Oncology Group (ECOG) performance status < 2

• Adequate major organ function

• Nutritional intake of at least 1500 calories per day at nutrition assessment

• Treatment started within 20-90 days post-op of surgery date.

• Informed consent

Exclusion Criteria:

• Less than 70 years of age

Related Conditions & MeSH terms

• Stomach Neoplasms

Intervention

Drug:
• cisplatinum combined with infusional fluorouracil (5 FU)
Continuous 5FU via intravenous PICC line + 4 doses of Cisplatin every 2 weeks

Locations

Country	Name	City	State
Canada	Princess Margaret Hospital	Toronto	Ontario

Sponsors (2)

Lead Sponsor	Collaborator
University Health Network, Toronto	Princess Margaret Hospital, Canada

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Phase I and II: Acute toxicity: assessed according to National Cancer Institute of Canada (NCIC) and Radiation Therapy Oncology Group (RTOG) toxicity assessment criteria.		10 years
Primary	Phase II: Comparison of acute toxicity rates with those observed in their previous study of 20 patients treated similarly to the SWOG INT 0116 protocol.		10 year
Secondary	Monitor 1 and 2 year local recurrence		10 years
Secondary	Survival and disease-specific survival		10 years